Bennicas & Associates, Inc. Abb Vie Inc. Transaction History

Bennicas & Associates, Inc.

$157 Million
Q4 2022

A detailed history of Bennicas & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Bennicas & Associates, Inc. holds 35,383 shares of ABBV stock, worth $6.21 Million. This represents 3.65% of its overall portfolio holdings.

Number of Shares

35,383

Previous 35,383 -0.0%

Holding current value

$6.21 Million

Previous $5.72 Million 0.05%

% of portfolio

3.65%

Previous 3.3%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 12, 2023	SELL	$138.31 - $165.87 $127,936 - $153,429	-925 Reduced 2.55%	35,383 $5.72 Million
Q3 2022 Oct 13, 2022	SELL	$134.21 - $153.93 $53,684 - $61,572	-400 Reduced 1.09%	36,308 $4.87 Million
Q2 2022 Jul 12, 2022	SELL	$137.62 - $174.96 $10,321 - $13,122	-75 Reduced 0.2%	36,708 $5.62 Million
Q1 2022 Apr 15, 2022	SELL	$131.98 - $163.75 $547,717 - $679,562	-4,150 Reduced 10.14%	36,783 $5.96 Million
Q4 2021 Jan 14, 2022	SELL	$107.43 - $135.93 $18,800 - $23,787	-175 Reduced 0.43%	40,933 $5.54 Million
Q3 2021 Oct 08, 2021	SELL	$106.4 - $120.78 $31,920 - $36,234	-300 Reduced 0.72%	41,108 $4.43 Million
Q1 2021 Apr 15, 2021	SELL	$102.3 - $112.62 $235,290 - $259,026	-2,300 Reduced 5.26%	41,408 $4.48 Million
Q4 2020 Jan 15, 2021	SELL	$80.49 - $108.67 $28,171 - $38,034	-350 Reduced 0.79%	43,708 $4.68 Million
Q3 2020 Oct 15, 2020	SELL	$85.91 - $100.83 $18,642 - $21,880	-217 Reduced 0.49%	44,058 $3.86 Million
Q2 2020 Jul 14, 2020	SELL	$73.37 - $98.18 $25,679 - $34,363	-350 Reduced 0.78%	44,275 $4.35 Million
Q1 2020 Apr 15, 2020	SELL	$64.5 - $97.79 $246,712 - $374,046	-3,825 Reduced 7.89%	44,625 $3.4 Million
Q4 2019 Jan 17, 2020	SELL	$72.13 - $90.25 $447,206 - $559,550	-6,200 Reduced 11.34%	48,450 $4.29 Million
Q3 2019 Oct 07, 2019	BUY	$62.98 - $75.72 $2.51 Million - $3.02 Million	39,917 Added 270.94%	54,650 $4.14 Million
Q2 2019 Jul 12, 2019	SELL	$65.7 - $83.98 $13,797 - $17,635	-210 Reduced 1.41%	14,733 $1.07 Million
Q1 2019 Apr 16, 2019	SELL	$77.14 - $90.79 $7,714 - $9,079	-100 Reduced 0.66%	14,943 $1.2 Million
Q4 2018 Jan 18, 2019	SELL	$77.85 - $96.01 $7,784 - $9,601	-100 Reduced 0.66%	15,043 $1.39 Million
Q2 2018 Jul 20, 2018	SELL	$89.78 - $106.23 $4,489 - $5,311	-50 Reduced 0.33%	15,143 $1.4 Million
Q1 2018 Apr 20, 2018	SELL	$92.01 - $123.21 $96,610 - $129,370	-1,050 Reduced 6.46%	15,193 $1.44 Million
Q4 2017 Jan 24, 2018	SELL	$89.56 - $98.21 $125,384 - $137,494	-1,400 Reduced 7.94%	16,243 $1.57 Million
Q3 2017 Oct 25, 2017	BUY	$69.85 - $89.22 $1.23 Million - $1.57 Million	17,643	17,643 $1.57 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bennicas & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bennicas & Associates, Inc. with notifications on news.

Account

Bennicas & Associates, Inc. Abb Vie Inc. Transaction History